Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | APEX1 | P27695 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.41 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.39 |
| ▸ | HRH2 | P25021 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | DGKA | P23743 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12768420 | 0.97 | POLB (0.46) | POLBAPEX1HTTTDP1TSHR | |
| SCHEMBL13882618 | 0.95 | POLB (0.53) | POLBAPEX1HTTTDP1TSHR | |
| SCHEMBL19294804 | 0.95 | POLB (0.53) | POLBAPEX1HTTTDP1TSHR | |
| SCHEMBL9480987 | 0.94 | POLB (0.51) | POLBAPEX1HTTTDP1TSHR | |
| SCHEMBL9480980 | 0.94 | POLB (0.51) | POLBAPEX1HTTTDP1TSHR | |
| SCHEMBL1532003 | 0.93 | POLB (0.47) | POLBAPEX1HTTTDP1TSHR | |
| SCHEMBL1531902 | 0.93 | POLB (0.47) | POLBAPEX1HTTTDP1TSHR | |
| SCHEMBL13531287 | 0.93 | POLB (0.47) | POLBAPEX1HTTTDP1TSHR | |
| SCHEMBL1927971 | 0.93 | POLB (0.47) | POLBAPEX1HTTTDP1TSHR | |
| SCHEMBL12768417 | 0.93 | POLB (0.47) | POLBAPEX1HTTTDP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7910019-B2 | Mesogen containing compounds | TRANSITIONS OPTICAL, INC. (US) | 2011-03-22 | — | — | US | disclosed |
| US-20100014010-A1 | FORMULATIONS COMPRISING MESOGEN CONTAINING COMPOUNDS | TRANSITIONS OPTICAL, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-20090326186-A1 | MESOGEN CONTAINING COMPOUNDS | TRANSITIONS OPTICAL, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090323011-A1 | MESOGEN CONTAINING COMPOUNDS | TRANSITIONS OPTICAL, INC. (US) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100014010-A1 | FORMULATIONS COMPRISING MESOGEN CONTAINING COMPOUNDS | MYOC, RARG, MTX2 | POLB 496/4885APEX1 3448/4885HTT 794/4885 |
| US-20090326186-A1 | MESOGEN CONTAINING COMPOUNDS | MYOC, BMP2, RARG | POLB 297/4885APEX1 2951/4885HTT 1202/4885 |
| US-20090323011-A1 | MESOGEN CONTAINING COMPOUNDS | MYOC, BMP2, RARG | POLB 297/4885APEX1 2951/4885HTT 1202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.